Personal Finance

This Vaccine Stock Soars 46% After $1.1 Billion AstraZeneca Deal

Icosavax stock soared 47% in Tuesday premarket trading after the Seattle-based vaccine developer reached a deal to be acquired by pharmaceutical giant AstraZeneca.

Continue reading this article with a Barron’s subscription.

View Options

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button